Pharmacokinetics of AGO178 in Participants With Liver Impairment
Status:
Completed
Trial end date:
2011-09-02
Target enrollment:
Participant gender:
Summary
AGO178 was developed for the treatment of depression. A new formulation is being tested in
the present study: a tablet to be placed and dissolved under the tongue (sublingual tablet).
The goal of this trial was to study the pharmacokinetics of agomelatine given as sublingual
tablet in participants with liver impairment and to compare the results to those of healthy
volunteers who receive the same treatment.